Skip to content
10-K

Annual Report

JASPER THERAPEUTICS, INC. JSPR JSPRW

0001213900-26-036426

← back to feed
Filed
Mar 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 19.17M sh
Shares Diluted FY 2025 · Dec 31, 2024 14.58M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$77.16M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$62.6M
Cash And Equivalents FY 2025 · Dec 31, 2025 $28.69M
Cash And Equivalents FY 2025 · Dec 31, 2024 $71.64M
Stockholders Equity FY 2025 · Dec 31, 2025 $4.15M
Stockholders Equity FY 2025 · Dec 31, 2024 $61.67M
Stockholders Equity FY 2025 · Dec 31, 2023 $78.44M
Current Liabilities FY 2025 · Dec 31, 2025 $13.2M
Current Liabilities FY 2025 · Dec 31, 2024 $15.24M
Total Liabilities FY 2025 · Dec 31, 2025 $31.63M
Total Liabilities FY 2025 · Dec 31, 2024 $18.23M
Current Assets FY 2025 · Dec 31, 2025 $34.65M
Current Assets FY 2025 · Dec 31, 2024 $75.81M
Total Assets FY 2025 · Dec 31, 2025 $35.78M
Total Assets FY 2025 · Dec 31, 2024 $79.9M
Eps Diluted FY 2025 · Dec 31, 2025 −$3.95
Eps Diluted FY 2025 · Dec 31, 2024 −$4.89
Eps Basic FY 2025 · Dec 31, 2025 −$3.95
Eps Basic FY 2025 · Dec 31, 2024 −$4.89
Sga Expense FY 2025 · Dec 31, 2025 $20.78M
Sga Expense FY 2025 · Dec 31, 2024 $20.42M
Rd Expense FY 2025 · Dec 31, 2025 $63.1M
Rd Expense FY 2025 · Dec 31, 2024 $55.82M
Net Income FY 2025 · Dec 31, 2025 −$75.8M
Net Income FY 2025 · Dec 31, 2024 −$71.27M
Operating Income FY 2025 · Dec 31, 2025 −$83.88M
Operating Income FY 2025 · Dec 31, 2024 −$76.24M
Cost Of Revenue FY 2025 · Dec 31, 2025 $41.64M
Cost Of Revenue FY 2025 · Dec 31, 2024 $34.27M